547 related articles for article (PubMed ID: 16826218)
1. Bortezomib: efficacy comparisons in solid tumors and hematologic malignancies.
Caravita T; de Fabritiis P; Palumbo A; Amadori S; Boccadoro M
Nat Clin Pract Oncol; 2006 Jul; 3(7):374-87. PubMed ID: 16826218
[TBL] [Abstract][Full Text] [Related]
2. Proteasome inhibition: a new approach for the treatment of malignancies.
Spano JP; Bay JO; Blay JY; Rixe O
Bull Cancer; 2005 Nov; 92(11):E61-6, 945-52. PubMed ID: 16316823
[TBL] [Abstract][Full Text] [Related]
3. Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies.
Ludwig H; Khayat D; Giaccone G; Facon T
Cancer; 2005 Nov; 104(9):1794-807. PubMed ID: 16178003
[TBL] [Abstract][Full Text] [Related]
4. Bortezomib, a novel proteasome inhibitor, in the treatment of hematologic malignancies.
Jackson G; Einsele H; Moreau P; Miguel JS
Cancer Treat Rev; 2005 Dec; 31(8):591-602. PubMed ID: 16298074
[TBL] [Abstract][Full Text] [Related]
5. Bortezomib: a novel therapy approved for multiple myeloma.
Richardson PG; Anderson KC
Clin Adv Hematol Oncol; 2003 Oct; 1(10):596-600. PubMed ID: 16258456
[TBL] [Abstract][Full Text] [Related]
6. Proteasome inhibition as a therapeutic strategy for hematologic malignancies.
Mitsiades CS; Mitsiades N; Hideshima T; Richardson PG; Anderson KC
Expert Rev Anticancer Ther; 2005 Jun; 5(3):465-76. PubMed ID: 16001954
[TBL] [Abstract][Full Text] [Related]
7. Proteasome inhibition for treatment of multiple myeloma: clinical update.
Stadtmauer EA
J Natl Compr Canc Netw; 2004 Nov; 2 Suppl 4():S10-5. PubMed ID: 19795531
[TBL] [Abstract][Full Text] [Related]
8. Proteasome inhibitors in cancer therapy.
Orlowski RZ
Methods Mol Biol; 2005; 301():339-50. PubMed ID: 15917644
[TBL] [Abstract][Full Text] [Related]
9. Bortezomib and its role in the management of patients with multiple myeloma.
Orlowski RZ
Expert Rev Anticancer Ther; 2004 Apr; 4(2):171-9. PubMed ID: 15056047
[TBL] [Abstract][Full Text] [Related]
10. The role of bortezomib in the treatment of lymphoma.
Barr P; Fisher R; Friedberg J
Cancer Invest; 2007 Dec; 25(8):766-75. PubMed ID: 18058474
[TBL] [Abstract][Full Text] [Related]
11. Bortezomib: a valuable new antineoplastic strategy in multiple myeloma.
Bladé J; Cibeira MT; Rosiñol L
Acta Oncol; 2005; 44(5):440-8. PubMed ID: 16118077
[TBL] [Abstract][Full Text] [Related]
12. [Proteasome inhibitor bortezomib as an anticancer drug].
Yasui H; Hideshima T
Tanpakushitsu Kakusan Koso; 2006 Aug; 51(10 Suppl):1251-6. PubMed ID: 16922383
[No Abstract] [Full Text] [Related]
13. Pharmacology, pharmacokinetics, and practical applications of bortezomib.
Schwartz R; Davidson T
Oncology (Williston Park); 2004 Dec; 18(14 Suppl 11):14-21. PubMed ID: 15688598
[TBL] [Abstract][Full Text] [Related]
14. Proteasome inhibition in multiple myeloma.
Kropff M; Bisping G; Wenning D; Berdel WE; Kienast J
Eur J Cancer; 2006 Jul; 42(11):1623-39. PubMed ID: 16820291
[TBL] [Abstract][Full Text] [Related]
15. Bortezomib in multiple myeloma.
Mateos MV; San Miguel JF
Best Pract Res Clin Haematol; 2007 Dec; 20(4):701-15. PubMed ID: 18070714
[TBL] [Abstract][Full Text] [Related]
16. The role of proteasome in malignant diseases.
Moran E; Nencioni A
J BUON; 2007 Sep; 12 Suppl 1():S95-9. PubMed ID: 17935285
[TBL] [Abstract][Full Text] [Related]
17. Proteasome inhibitors as therapeutics.
Mitsiades CS; Mitsiades N; Hideshima T; Richardson PG; Anderson KC
Essays Biochem; 2005; 41():205-18. PubMed ID: 16250907
[TBL] [Abstract][Full Text] [Related]
18. Bortezomib, a newly approved proteasome inhibitor for the treatment of multiple myeloma: nursing implications.
Colson K; Doss DS; Swift R; Tariman J; Thomas TE
Clin J Oncol Nurs; 2004 Oct; 8(5):473-80. PubMed ID: 15515281
[TBL] [Abstract][Full Text] [Related]
19. Proteasome inhibitors in pediatric cancer treatment.
Bachmann AS
Hawaii Med J; 2008 Sep; 67(9):247-9. PubMed ID: 18853901
[TBL] [Abstract][Full Text] [Related]
20. Expanding role of bortezomib in multiple myeloma: nursing implications.
Colson K; Doss DS; Swift R; Tariman J
Cancer Nurs; 2008; 31(3):239-49. PubMed ID: 18453881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
